Biospecimens are invaluable in pinpointing de novo therapeutic drug targets; they are also a critical tool for the identification of novel cancer resistance mechanisms and oncogenic pathways. Here, we highlight keys to selecting the biospecimens best suited to drive success for IO research and development.